Predictions
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€38.00
02.02.24
02.02.24
-
-
03.02.24
03.02.24
Could be worthwhile Investment >10% per year
Johnson & Johnson
Start price
Target price
Perf. (%)
€153.36
24.01.23
24.01.23
€160.00
24.01.24
24.01.24
-4.60%
25.01.24
25.01.24
Could be worthwhile Investment >10% per year
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€357.30
13.12.23
13.12.23
€396.00
04.07.24
04.07.24
10.15%
24.01.24
24.01.24
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€529.00
18.12.23
18.12.23
€558.00
18.12.24
18.12.24
6.62%
06.01.24
06.01.24
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€68.08
03.01.23
03.01.23
-
03.01.24
03.01.24
-32.29%
28.12.23
28.12.23
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High dividend yield expected
Good rating
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€526.00
14.12.23
14.12.23
€558.00
14.12.24
14.12.24
0.57%
18.12.23
18.12.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Johnson & Johnson
Start price
Target price
Perf. (%)
€136.50
15.11.23
15.11.23
€165.00
15.12.23
15.12.23
4.25%
16.12.23
16.12.23
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€568.50
11.10.23
11.10.23
€558.00
11.10.24
11.10.24
-7.48%
14.12.23
14.12.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.86
04.11.23
04.11.23
€89.00
04.12.23
04.12.23
-4.82%
05.12.23
05.12.23
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€239.95
01.04.22
01.04.22
€330.00
18.12.23
18.12.23
41.68%
14.11.23
14.11.23
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€370.05
04.11.22
04.11.22
€610.00
04.11.23
04.11.23
44.17%
05.11.23
05.11.23
Top 10 in its market
Could be worthwhile Investment >10% per year
High dividend yield expected
Innovative